Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives $11.71 Consensus Price Target from Brokerages

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) has earned a consensus recommendation of “Buy” from the seven analysts that are presently covering the firm, MarketBeat.com reports. Six research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among brokers that have covered the stock in the last year is $11.71.

Several equities analysts have commented on the company. Oppenheimer assumed coverage on Rani Therapeutics in a report on Friday, August 2nd. They set an “outperform” rating and a $17.00 price target on the stock. HC Wainwright decreased their price target on shares of Rani Therapeutics from $13.00 to $9.00 and set a “buy” rating on the stock in a research note on Friday, August 16th.

Institutional Investors Weigh In On Rani Therapeutics

An institutional investor recently bought a new position in Rani Therapeutics stock. Marshall Wace LLP acquired a new stake in Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 21,247 shares of the company’s stock, valued at approximately $81,000. 30.19% of the stock is currently owned by institutional investors.

Rani Therapeutics Price Performance

NASDAQ RANI opened at $2.02 on Friday. The company has a 50 day simple moving average of $2.54 and a 200-day simple moving average of $3.88. The company has a debt-to-equity ratio of 3.10, a current ratio of 1.93 and a quick ratio of 1.93. The firm has a market capitalization of $101.85 million, a price-to-earnings ratio of -1.57 and a beta of 0.12. Rani Therapeutics has a 52-week low of $1.82 and a 52-week high of $8.75.

Rani Therapeutics (NASDAQ:RANI) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.03. Equities research analysts predict that Rani Therapeutics will post -0.98 earnings per share for the current fiscal year.

Rani Therapeutics Company Profile

Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.